Sun Pharma Organon acquisition ratings boost
Analysis based on 7 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The investment-grade ratings from Moody's and S&P signal improved creditworthiness for Sun Pharma, likely lowering its borrowing costs and supporting its ability to finance the large acquisition. The deal is expected to nearly double Sun Pharma's revenue and enhance its competitive position, which could positively influence its stock price and credit spreads.
Moody s Ratings and S&P Global Ratings assigned investment-grade credit ratings to Sun Pharma Industries, India's largest pharmaceutical company, in connection with its proposed USD 11.75 billion acquisition of US-based Organon & Co. S&P assigned a preliminary 'BBB+' long-term issuer credit rating, while Moody's assigned a 'Baa1' long-term issuer rating, both with a stable outlook. The rating actions follow Sun Pharma's binding bid in April 2026 to acquire 100% of Organon at an enterprise value of USD 11.75 billion, with the transaction expected to close by March 2027 subject to regulatory approvals. The agencies expect the acquisition to nearly double Sun Pharma's revenue to about USD 14 billion by fiscal 2028 and to strengthen its scale, geographic reach, and growth platforms in women's health and biosimilars. Sun Pharma has secured a USD 12 billion committed acquisition bridge loan from a syndicate of international banks and held approximately USD 3.6 billion in cash as of March 31, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard